Literature DB >> 10227928

Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia.

K C Fearon1, M D Barber, J S Falconer, D C McMillan, J A Ross, T Preston.   

Abstract

Patients with pancreatic cancer frequently develop the syndrome of cancer cachexia. Pro-inflammatory cytokines have been strongly implicated in the pathogenesis of this syndrome. In patients with pancreatic cancer an acute-phase response (an index of pro-inflammatory cytokine activity) is associated with accelerated weight loss, hypermetabolism, anorexia, and a shortened duration of survival. However, little is known about the primary significance of the acute-phase response in terms of altered hepatic export protein synthesis rates and its potential impact on the body's nitrogen economy. In a recent series of studies on weight-losing pancreatic cancer patients with hypoalbuminemia we have demonstrated albumin synthesis to be unaltered whereas fibrinogen synthesis is increased two- to threefold compared with healthy controls. Because of the mismatch in amino acid composition between the body's main labile amino acid reserve (skeletal muscle) and that of acute-phase proteins, these results lend support to the concept that in pancreatic cancer the reprioritization of body protein metabolism during an acute-phase response may well be a significant factor in the loss of lean tissue in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227928     DOI: 10.1007/pl00012351

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  57 in total

1.  Immunomodulation in surgical practice.

Authors:  R Andersson; B Andersson; E Andersson; G Eckerwall; M Nordén; B Tingstedt
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 2.  Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.

Authors:  Carlos Camps; Vega Iranzo; Roy M Bremnes; Rafael Sirera
Journal:  Support Care Cancer       Date:  2006-07-04       Impact factor: 3.603

Review 3.  Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

Authors:  Ying Zeng; Agnieszka A Rucki; Xu Che; Lei Zheng
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

5.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

Review 6.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

7.  Pancreatic cancer serum detection using a lectin/glyco-antibody array method.

Authors:  Chen Li; Diane M Simeone; Dean E Brenner; Michelle A Anderson; Kerby A Shedden; Mack T Ruffin; David M Lubman
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

8.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

Review 9.  Non-surgical oncology - Guidelines on Parenteral Nutrition, Chapter 19.

Authors:  J Arends; G Zuercher; A Dossett; R Fietkau; M Hug; I Schmid; E Shang; A Zander
Journal:  Ger Med Sci       Date:  2009-11-18

10.  Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Authors:  Jeannine Bachmann; Knut Ketterer; Christiane Marsch; Kerstin Fechtner; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2009-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.